DK0702560T3 - Immunforstærkning ved intermitterende interleukin-2 behandling - Google Patents

Immunforstærkning ved intermitterende interleukin-2 behandling

Info

Publication number
DK0702560T3
DK0702560T3 DK94920673T DK94920673T DK0702560T3 DK 0702560 T3 DK0702560 T3 DK 0702560T3 DK 94920673 T DK94920673 T DK 94920673T DK 94920673 T DK94920673 T DK 94920673T DK 0702560 T3 DK0702560 T3 DK 0702560T3
Authority
DK
Denmark
Prior art keywords
period
therapy
intermittent
treatment
infusions
Prior art date
Application number
DK94920673T
Other languages
English (en)
Inventor
H Clifford Lane
Joseph A Kovacs
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK0702560T3 publication Critical patent/DK0702560T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK94920673T 1993-05-19 1994-05-19 Immunforstærkning ved intermitterende interleukin-2 behandling DK0702560T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/063,315 US5419900A (en) 1993-05-19 1993-05-19 Immunologic enhancement with intermittent interleukin-2 therapy
PCT/US1994/005397 WO1994026293A1 (en) 1993-05-19 1994-05-19 Immunologic enhancement with intermittent interleukin-2 therapy

Publications (1)

Publication Number Publication Date
DK0702560T3 true DK0702560T3 (da) 2002-02-25

Family

ID=22048393

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94920673T DK0702560T3 (da) 1993-05-19 1994-05-19 Immunforstærkning ved intermitterende interleukin-2 behandling

Country Status (11)

Country Link
US (3) US5419900A (da)
EP (1) EP0702560B1 (da)
JP (1) JP4275193B2 (da)
AT (1) ATE208206T1 (da)
AU (1) AU691504B2 (da)
CA (1) CA2163219A1 (da)
DE (1) DE69428992T2 (da)
DK (1) DK0702560T3 (da)
ES (1) ES2167370T3 (da)
PT (1) PT702560E (da)
WO (1) WO1994026293A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696079A (en) * 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
RU2117472C1 (ru) * 1995-08-22 1998-08-20 Андрей Юрьевич Егоров Противоопухолевое средство местно-резорбтивного действия на основе интерлейкина-2 человека
JP2002515730A (ja) * 1995-10-16 2002-05-28 カイロン コーポレイション 遺伝子発現を変調する因子のスクリーニング方法
KR100220645B1 (ko) * 1997-07-04 1999-09-15 구광시 벤젠유도체의 제조방법
AU1539699A (en) * 1997-11-24 1999-06-15 Johnson T. Wong Methods for treatment of hiv or other infections using a t cell or viral activator and anti-retroviral combination therapy
ATE384795T1 (de) * 1998-12-31 2008-02-15 Novartis Vaccines & Diagnostic Modifizierte hiv env polypeptide
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
EP1141314A2 (en) * 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US6921530B1 (en) * 1999-09-24 2005-07-26 Cornell Research Foundation, Inc. Low dose IL-2 for potentiation of immunity
CA2421409A1 (fr) * 2000-09-08 2002-03-14 Aventis Pasteur Utilisation de lipopeptides pour l'immunotherapie des sujets vih+
FR2813793B1 (fr) * 2000-09-08 2003-01-24 Aventis Pasteur Utilisation de lipopeptides pour l'immunotherapie des sujets vih+
US6579521B2 (en) * 2000-10-20 2003-06-17 Chiron Corporation Methods of therapy for HIV infection
US20060159657A1 (en) * 2001-06-14 2006-07-20 Macromed, Incorporated Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
US20030003074A1 (en) * 2001-06-14 2003-01-02 Macromed, Inc. Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
EP1409694A4 (en) * 2001-07-05 2006-02-08 Chiron Corp POLYNUCLEOTIDES ENCODING ANTIGENIC POLYPEPTIDES OF HIV SUBTYPE B AND / OR SUBTYPE C, POLYPEPTIDES AND USES THEREOF
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CA2456470A1 (en) * 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
RU2201762C1 (ru) * 2001-10-09 2003-04-10 Свадовский Александр Игоревич Способ лечения внутримозговой опухоли головного мозга
EP1676132B1 (en) 2003-10-21 2014-01-22 Cedars-Sinai Medical Center Combination of chemotherapy and administration of glioma-antigen-pulsed dendritic cells in the treatment of glioma
US20070098685A1 (en) * 2005-01-19 2007-05-03 Brand Stephen J Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039969A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
PL2427485T3 (pl) 2009-05-07 2017-10-31 Immunocellular Therapeutics Ltd Epitopy CD133
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
CN104395344B (zh) 2012-05-07 2019-08-13 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
WO2014127296A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Cancer vaccines and vaccination methods
AU2015328163B2 (en) 2014-10-09 2020-10-15 Dana-Farber Cancer Institute, Inc. Multiple-variable IL-2 dose regimen for treating immune disorders
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
US4863730A (en) 1986-03-21 1989-09-05 Cenfold Holdings, S.A. Immunotherapy for AIDS patients
US4868157A (en) 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 2-amino-1,2-dideoxy-D-glucose derivatives as host resistance enhancers in AIDS-immunocompromised hosts and methods of use
US4866157A (en) * 1987-11-10 1989-09-12 Sugio Otani Thermosetting aromatic resin composition
DE3818054C2 (de) * 1988-05-27 1994-02-17 Biotest Pharma Gmbh Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen
FR2653020B1 (fr) * 1989-10-17 1993-03-26 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies.
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
ATE180276T1 (de) 1990-01-26 1999-06-15 Washington Res Found Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten
FR2660863B1 (fr) * 1990-04-17 1994-01-21 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre.
US5696079A (en) 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy

Also Published As

Publication number Publication date
AU7137794A (en) 1994-12-12
JP4275193B2 (ja) 2009-06-10
WO1994026293A1 (en) 1994-11-24
EP0702560A1 (en) 1996-03-27
AU691504B2 (en) 1998-05-21
US6190656B1 (en) 2001-02-20
PT702560E (pt) 2002-04-29
DE69428992D1 (de) 2001-12-13
JPH09500362A (ja) 1997-01-14
US5419900A (en) 1995-05-30
ATE208206T1 (de) 2001-11-15
US6548055B1 (en) 2003-04-15
DE69428992T2 (de) 2002-08-14
CA2163219A1 (en) 1994-11-24
EP0702560B1 (en) 2001-11-07
ES2167370T3 (es) 2002-05-16

Similar Documents

Publication Publication Date Title
PT702560E (pt) Intensificacao imunologica com terapia intermitente de interleucina-2
KR950700333A (ko) 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로부터의 제조 방법(improved alpha interferon composition and method for its production from human peripheral blood leukocytes)
BG91270A (bg) Антивирусно и антибактериално средство и метод за използването му
ES2087061T3 (es) Utilizacion de ribosido o ribotido de aica para la fabricacion de un medicamento contra la crisis cardiaca o el infarto de miocardio en los pacientes que sufren de ateroesclerosis.
MY103212A (en) Zinc-protamine-alpha interferon complex
DE69333580D1 (de) Immunregulation über die cd28-route
MX9203439A (es) Una citocina mamifera, il-11
ES2032382T3 (es) Metodo para preparar un medicamento para la prevencion o tratamiento de la endometriosis.
DK0911033T4 (da) Anvendelse af konsensusinterferon til reduktion af bivirkningerne af interferonbehandling i viral hepatitis
ES2177780T3 (es) Medicamentos para el tratamiento de enfermedades autoinmunes usando interferon tau.
ATE74510T1 (de) Adoptivimmuntherapie als behandlungsmodalitaet bei menschen.
ATE153856T1 (de) Zusammensetzung zur stimulierung des immunsystems
WO1994026293B1 (en) Immunologic enhancement with intermittent interleukin-2 therapy
GB1499035A (en) Antistaphylococcus human immune globulin and method of preparing same
ES2078893T3 (es) Sistema de entrega de drogas transdermica pulsatoria.
FR2662942B1 (fr) Medicament immunostimulant a base de glycopeptidolipides polaires de mycobacterium chelonae.
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
RU95104171A (ru) Средство для лечения иммуносупрессии при сепсисе у человека и способ ее лечения
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
OA08768A (fr) Traitement du virus su SIDA par l'interféron alpha humain recombinant.
Lane et al. Immunologic enhancement with intermittent interleukin-2 therapy
DK0651649T3 (da) Fremgangsmåde til administrering af opløsninger af granulocytkolonistimulerende faktor
Yokoyama et al. Role of lymphocyte activation by substance P in rheumatoid arthritis
Whiteside The natural killer (NK) cell and synergistic antitumor effects of interferon-gamma and interleukin-2
Lein Immune-based therapies